Updated Jul 16, 2026
Bumpus Namandje has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $28K.
Bumpus Namandje is listed as a director of Recursion Pharmaceuticals, Inc. in the most recent SEC filing dated 2026-06-04. Recursion is a biotechnology company focused on AI-driven drug discovery. The SEC filing provides the executive role (Director) but does not provide additional biographical details within this context.
| Role | Director |
|---|---|
| Notability | 60/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-22 | RXRX | RECURSION PHARMACEUTICALS, INC. | S — Open-market sale | 4.0K | $3.18 | $13K |
| 2026-06-22 | RXRX | RECURSION PHARMACEUTICALS, INC. | A — Grant or award | 88.4K | $0.00 | |
| 2026-06-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | S — Open-market sale | 4.4K | $3.54 | $16K |
Bumpus Namandje is listed as a director of Recursion Pharmaceuticals, Inc. in the most recent SEC filing dated 2026-06-04. Recursion is a biotechnology company focused on AI-driven drug discovery. The SEC filing provides the executive role (Director) but does not provide additional biographical details within this context.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($28K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Bumpus Namandje profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.